The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide, igniting an …

Background & Aims Given that gastrointestinal (GI) symptoms are a prominent extrapulmonary
manifestation of COVID-19, we investigated intestinal infection with SARS-CoV-2, its …

Emerging data suggest that locoregional cancer therapeutic approaches with oncolytic
viruses can lead to systemic anti-tumour immunity, although the appropriate targets for …

Gastrointestinal symptoms are common in COVID-19 patients but the nature of the gut
immune response to SARS-CoV-2 remains poorly characterized, partly due to the difficulty of …

Given that gastrointestinal (GI) symptoms are a prominent extrapulmonary manifestation of
coronavirus disease 2019 (COVID-19), we investigated intestinal infection with severe acute …

Using the immune system to control cancer has been investigated for over a century. Yet it
is only over the last several years that therapeutic agents acting directly on the immune …

Background and aims Immune dysregulation caused by SARS-CoV-2 infection is thought to
play a pathogenic role in COVID-19. SARS-CoV-2 can infect a variety of host cells, including …

Functional characterization of the microbiome’s influence on host physiology has been
dominated by a few characteristic example strains that have been studied in detail. However, the …

cAMP signaling pathways can both stimulate and inhibit the development of cancer; however,
the sources of cAMP important for tumorigenesis remain poorly understood. Soluble …

Cancer immunotherapy with Newcastle disease virus (NDV) dates back to 1960s, when
intratumoral treatment of a cervical cancer patient was noted to result in an abscopal effect with …